Gain Therapeutics, Inc. Stock Analysis & AI Score
Gain Therapeutics, Inc. (GANX) has an ST Score of 45.4 (C+), driven by its Momentum (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.80 price target (+323.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Gain Therapeutics, Inc. (GANX) has an ST Score of 45.4 (C+), driven by its Momentum (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.80 price target (+323.9% upside).
- Strongest
- MomentumA
- Weakest
- ProfitabilityF
All factor grades
- MomentumA
- ForecastA
- ValuationB+
- Financial StrengthD+
- GrowthD
- ProfitabilityF
- Piotroski3/9
Contact
GANX stock: frequently asked questions
What is GANX's ST Score?
Gain Therapeutics, Inc. (GANX) has an ST Score of 45.4 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GANX a buy, hold, or sell?
Analysts rate GANX a Buy, with a price target of $7.80 (+323.9% vs the current price). Our ST Score grades it C+ (45.4/100). The ST Score is a data-driven signal, not a recommendation.
What are GANX's factor grades?
Valuation B+, Profitability F, Financial Strength D+, Momentum A, Growth D, Forecast A.
What is GANX's valuation grade?
Gain Therapeutics, Inc. (GANX) earns a valuation grade of B+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GANX's growth grade?
Gain Therapeutics, Inc. (GANX) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GANX's profitability grade?
Gain Therapeutics, Inc. (GANX) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GANX's financial strength grade?
Gain Therapeutics, Inc. (GANX) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GANX?
The average analyst price target for Gain Therapeutics, Inc. (GANX) is $7.80 from 8 analysts, which is +323.9% versus the recent price of $1.84.
What is GANX's Piotroski score?
Gain Therapeutics, Inc. (GANX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.